[go: up one dir, main page]

MX2023008453A - Metodos de tratamiento para el abuso de sustancias. - Google Patents

Metodos de tratamiento para el abuso de sustancias.

Info

Publication number
MX2023008453A
MX2023008453A MX2023008453A MX2023008453A MX2023008453A MX 2023008453 A MX2023008453 A MX 2023008453A MX 2023008453 A MX2023008453 A MX 2023008453A MX 2023008453 A MX2023008453 A MX 2023008453A MX 2023008453 A MX2023008453 A MX 2023008453A
Authority
MX
Mexico
Prior art keywords
methods
substance abuse
treating substance
ketamine
subject
Prior art date
Application number
MX2023008453A
Other languages
English (en)
Inventor
Jonathan Sporn
Jay Kranzler
Jeffrey M Witkin
Original Assignee
Perception Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perception Neuroscience Inc filed Critical Perception Neuroscience Inc
Publication of MX2023008453A publication Critical patent/MX2023008453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación proporciona un método para tratar un trastorno por uso de sustancias en un sujeto, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de una composición que comprende R(-)-ketamina o una sal farmacéuticamente aceptable de la misma, en donde la composición está sustancialmente libre de S(+)-ketamina o una sal farmacéuticamente aceptable de la misma.
MX2023008453A 2018-05-04 2020-11-03 Metodos de tratamiento para el abuso de sustancias. MX2023008453A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862666813P 2018-05-04 2018-05-04

Publications (1)

Publication Number Publication Date
MX2023008453A true MX2023008453A (es) 2023-07-27

Family

ID=68386073

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011653A MX2020011653A (es) 2018-05-04 2019-05-03 Métodos de tratamiento para el abuso de sustancias.
MX2023008453A MX2023008453A (es) 2018-05-04 2020-11-03 Metodos de tratamiento para el abuso de sustancias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020011653A MX2020011653A (es) 2018-05-04 2019-05-03 Métodos de tratamiento para el abuso de sustancias.

Country Status (8)

Country Link
US (2) US11426367B2 (es)
EP (1) EP3813808A4 (es)
JP (2) JP2021523228A (es)
CN (2) CN112533595A (es)
AU (2) AU2019262197B2 (es)
CA (1) CA3099293A1 (es)
MX (2) MX2020011653A (es)
WO (1) WO2019213551A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2020221993A1 (en) * 2019-05-02 2020-11-05 Closed Loop Medicine Ltd Methods and systems for providing personalised medicine to a patient
CA3172981A1 (en) * 2020-03-23 2021-09-30 Joseph Rustick Method for treatment of neurological disorders using synaptic pathway training
EP4146198A4 (en) 2020-05-08 2024-05-15 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
AU2022281358A1 (en) 2021-05-25 2023-11-23 Atai Therapeutics, Inc. New n,n-dimethyltryptamine salts and crystalline salt forms
AU2022287974A1 (en) 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
EP4408412A4 (en) * 2021-09-30 2025-07-16 ATAI Life Sciences AG COMPOSITIONS AND METHODS FOR TREATING HEADACHES
WO2023064363A1 (en) 2021-10-12 2023-04-20 Perception Neuroscience, Inc. R-ketamine salts and methods of use thereof
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
CA3245931A1 (en) 2022-03-14 2023-09-21 Perception Neuroscience, Inc. R-KETAMINE PHARMACEUTICAL FORMULATIONS
US11670410B1 (en) * 2022-04-13 2023-06-06 Green Sky Creations LLC Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition
EP4642445A2 (en) * 2022-12-28 2025-11-05 Perception Neuroscience, Inc. Methods of administering r-ketamine
US12420014B2 (en) 2023-06-05 2025-09-23 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs
WO2025160483A1 (en) * 2024-01-24 2025-07-31 Awakn Ls Europe Holdings Limited Oral transmucosal esketamine therapy for alcohol use disorder and substance use disorders

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US4670459A (en) * 1984-10-03 1987-06-02 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US5679714A (en) 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
MXPA02008144A (es) 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
BRPI0002693B8 (pt) 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
ATE432697T1 (de) 2002-11-18 2009-06-15 Yaupon Therapeutics Inc Analgetische verwendung von (s)-norketamin
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
ME01956B (me) 2005-09-28 2015-05-20 Auris Medical Ag Farmaceutske kompozicije za tretman poremećaja unutrašnjeg uva
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
KR20140136982A (ko) 2012-03-12 2014-12-01 얀센 파마슈티카 엔.브이. 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
US20140057988A1 (en) 2012-08-23 2014-02-27 Stuart WEG Anxiolytic composition, formulation and method of use
CN116251084A (zh) 2013-03-15 2023-06-13 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
BR112015022972B1 (pt) 2013-03-15 2023-02-14 Janssen Pharmaceutica Nv Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma
US20140271765A1 (en) * 2013-03-15 2014-09-18 Titan Pharmaceuticals, Inc. Methods and device for treating opioid addiction
MX370506B (es) 2013-04-12 2019-12-16 Icahn School Med Mount Sinai Método para tratar trastorno de estrés post-traumático.
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
CA2936809A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
JP6545788B2 (ja) 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ．ベー． うつ病の治療方法
CN115521217A (zh) 2014-11-04 2022-12-27 阿莫萨治疗公司 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
EP4413979A3 (en) 2015-06-19 2024-11-20 Melt Pharmaceuticals, Inc. Pharmaceutical compositions for anesthesiological applications
HK1248578A1 (zh) 2015-06-27 2018-10-19 Shenox Pharmaceuticals, Llc 氯胺酮透皮递送系统
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
JP2019512528A (ja) 2016-03-25 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
RU2764716C2 (ru) 2016-08-26 2022-01-19 Экссива Уг (Хафтунгзбешрэнкт) Композиции и связанные с ними способы
US20200261442A1 (en) 2016-08-26 2020-08-20 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
WO2018075481A1 (en) * 2016-10-17 2018-04-26 Yale University Compounds, compositions and methods for treating or preventing depression and other diseases
US20180177743A1 (en) 2016-12-22 2018-06-28 Gary Jay Method of treating pain using racemic mixture of s-ketamine and r-ketamine
EP3562529A4 (en) 2016-12-27 2021-03-03 Action Medical Technologies, LLC APPARATUS AND METHOD FOR INJECTING MEDICINES
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CN110996946A (zh) 2017-05-25 2020-04-10 格莱泰施有限责任公司 用于治疗创伤后应激障碍的制剂
EP3641742A2 (en) 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
US20200405663A1 (en) 2017-09-27 2020-12-31 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
MX2020007479A (es) 2018-01-10 2020-11-24 Xwpharma Ltd Profármacos de ketamina, composiciones y usos de los mismos.
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
WO2019169165A1 (en) 2018-02-28 2019-09-06 Novocine Therapeutics, Llc Ketamine and ketamine-related compounds for the treatment of neurological disorders
EP3761970A4 (en) 2018-03-26 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
GB201809976D0 (en) 2018-06-18 2018-08-01 Neurocentrx Pharma Ltd Novel formulations
EP3813807A1 (en) 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
CA3113198A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3903775A4 (en) 2018-12-27 2022-10-12 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
HUE065684T2 (hu) 2019-01-11 2024-06-28 Alar Pharmaceuticals Inc Ketamin-pamoát és alkalmazása
WO2020198039A1 (en) 2019-03-23 2020-10-01 Sermone Sandra Ketamine for treatment of sensory processing deficits
US12234200B2 (en) 2019-04-16 2025-02-25 Janssen Pharmaceutica Nv Synthetic methods of preparing esketamine
CN114126596A (zh) 2019-05-15 2022-03-01 贝克森生物医药公司 用于皮下注射的氯胺酮制剂
US20220151955A1 (en) 2019-08-05 2022-05-19 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
US11007200B2 (en) 2019-08-21 2021-05-18 MediSynergics, LLC Cycloalkyl-diamines for the treatment of pain
RS67418B1 (sr) 2019-12-20 2025-12-31 Alar Pharmaceuticals Inc Injekcione formulacije pamoatnih soli ketamina sa dugotrajnim dejstvom
CN115190815B (zh) 2019-12-26 2024-06-18 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
MX2022009050A (es) 2020-01-22 2022-10-27 Seelos Therapeutics Inc Reduccion de los efectos secundarios de los antagonistas de nmda.
EP4125836A1 (en) 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
US20230121608A1 (en) 2020-04-07 2023-04-20 The Trustees Of Columbia University In The City Of New York Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety- Like Behavior
WO2021231905A1 (en) 2020-05-15 2021-11-18 The University Of Kansas Ketamine treatment for amyotrophic lateral sclerosis
WO2021252971A2 (en) 2020-06-12 2021-12-16 Bexson Biomedical, Inc. Systems and devices for controlled drug delivery
WO2021255737A1 (en) 2020-06-17 2021-12-23 Spirify Pharma Inc. Hydroxynorketamine analogues, compositions comprising same and methods of use thereof

Also Published As

Publication number Publication date
WO2019213551A1 (en) 2019-11-07
EP3813808A4 (en) 2022-01-26
CN112533595A (zh) 2021-03-19
CA3099293A1 (en) 2019-11-07
AU2025201945A1 (en) 2025-04-03
JP2024091801A (ja) 2024-07-05
JP2021523228A (ja) 2021-09-02
US20220347124A1 (en) 2022-11-03
EP3813808A1 (en) 2021-05-05
US20210259993A1 (en) 2021-08-26
AU2019262197B2 (en) 2024-12-19
MX2020011653A (es) 2021-02-09
AU2019262197A1 (en) 2020-11-26
US11426367B2 (en) 2022-08-30
CN118121577A (zh) 2024-06-04

Similar Documents

Publication Publication Date Title
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2022000143A (es) Metodos novedosos.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX2019007002A (es) Moduladores de linfocitos t reguladores multivalentes.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2018013517A (es) Anticuerpos anti-il-1r3 humanizados.
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
AR101740A1 (es) Terapia de combinación y composiciones
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2021002888A (es) Combinaciones farmacéuticas para el tratamiento de tumores que comprenden un anticuerpo anti cúmulo de diferenciación 19 (cd19) y una célula asesina natural.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2022003945A (es) Metodo para tratar vih con cabotegravir y rilpivirina.